Data collection
Information including the baseline demographic data, history of epilepsy, clinical characteristics including the etiologies of status epilepticus, seizure semiology on presentation, electroencephalogram (EEG) patterns, durations of status epilepticus, pharmacological treatments and the outcomes including the length of intensive care unit (ICU) stay, length of hospital stay, 30-day mortality and functional outcome upon discharge were recorded. Status epilepticus was defined as a single epileptic seizure lasting longer than 30 min or a series of epileptic seizures during which consciousness was not regained between seizures for longer than 30 min.
Seizure semiology on presentation were classified as convulsive status epilepticus (CSE) and non-convulsive status epilepticus (NCSE). The duration of SE was defined as the time from the beginning of CSE seizures or EEG confirmation in patients with NCSE until the response to SE treatment. Response to treatment was defined by either the stopping of motor seizures in patients with CSE or EEG showing burst suppression in cases of NCSE. Etiologies were categorized as breakthrough seizure, encephalitis/ meningitis, cerebrovascular accident (CVA), metabolic causes (including uremic and hepatic encephalopathy and hyponatremia), drug overdose/alcohol withdrawal, subarachnoid hemorrhage (SAH)/subdural hemorrhage (SDH), sepsis and hypoxic brain injury. If there was no clinical, biological or radiological evidence supporting a specific cause, the etiology was labeled as idiopathic. In cases SE was due to breakthrough seizure, the anti-epileptic drug (AED) level was recorded.
Functional status on discharge was defined by the Glasgow Outcome Score (GOS) which consists of five degrees of handicap [13] (1) Death within the first month. Poor outcome was defined as death or functional deterioration of one or more points on the GOS among survivors at discharge when compared with pre-admission states.
Statistical analysis
The data were analyzed by Statistical Package for Social Sciences (SPSS) Version 20. Categorical variables were compared by Chi-square test or Fisher's exact test where appropriate Continuous variables were analyzed with independent-sample t-test and Mann-Whitney-U test, respectively for parametric and non-parametric data. A p value of <0.05 was considered to be statistically significant. All p-values were 2-sided.
Results

Clinical characteristics
The clinical characteristic of subjects is presented in Table 1 . Eightyseven cases were identified over the study period. The mean age of subjects was 49.3 years (SD 14.9 years). Forty-eight subjects (56.3%) were male. Forty-eight (56.3%) subjects had history of epilepsy. Seventy-eight subjects (89.7%) had convulsive status epilepticus while 9 subjects (10.3%) had non-convulsive status epilepticus on presentation. Eighteen subjects (20.7%) had breakthrough seizure, which was the most common etiology for status epilepticus in the study cohort. Anti-epileptic drug level was checked in 86% of cases, in which low AED level was confirmed in 59.1% of cases. Among the nine cases with confirmed low AED level, two of them were secondary to recent medication titration and the remaining cases were due to poor drug compliance. The other causes of SE included central nervous system infection (n = 16, 18.4%), cerebrovascular accident, either acute symptomatic and chronic (n = 10, 11.5%), metabolic causes (n = 9, 10.3%), drug overdose/alcohol withdrawal (n = 7, 8.0%), hypoxic brain damage (n = 6, 6.9%), traumatic subarachnoid hemorrhage/subdural hemorrhage and sepsis (n = 4, 4.6%). No identifiable cause was found in 13 subjects (14.8%) ( Table 2) .
Treatment profiles
Thirty-seven subjects (42.5%) received a single anti-convulsant for seizure control while 28 subjects (32.2%) received two SD, standard deviation. Table 2 Mortality and outcomes of patients with various etiologies of status epilepticus.
Total SE cases, n (%) 30-day mortality, n (%) Poor outcome on discharge, n (%) anti-convulsants. Phenytoin was the most commonly used anti-convulsant (n = 75, 86.2%), followed by valproate (n = 36, 41.4%), carbamazepine (n = 19, 21.8%) and levetiracetam (n = 19, 21.8%). Forty-eight subjects (55.2%) received general anesthetic treatment. Midazolam was the most commonly used anesthetic agent (n = 41, 47.1%), followed by propofol (n = 19, 21.8%) and thiopentone (n = 8, 9.2%). Nine patients (10.3%) received immunotherapy. The indications of immunotherapy included suspected autoimmune encephalitis (n = 7, 8.0%) and central nervous system vasculitis (n = 2, 2.3%). Steroid was used in one subject (2.3%). Intravenous immunoglobulin was used in 6 subjects (6.9%). Combined plasmapharesis and intravenous immunoglobulin were used in one subject (1.1%) who suffered from suspected autoimmune encephalitis. Among the cases of suspected autoimmune encephalitis, anti-NMDA receptor antibody was checked in 4 cases, and anti-VGKC antibody was checked in 3 cases. All turned out to be negative.
Outcomes
The median length ICU stay was 5 days (IQR 8 days) and that of hospital stay was 14 days (IQR 20 days). The median duration of status epilepticus was 1 day (IQR 4 days). The 30-day mortality was 18.4%. Forty patients (46.0%) had poor outcome upon discharge. The 30-day mortality and poor outcome were further analyzed according to various etiologies (Table 2) . Patients admitted for SE due to breakthrough seizure (n = 18, 21%) had the best clinical outcome. The 30-day mortality in this group of patients was zero. Only two patients (11%) had poor outcome upon discharge. Patients admitted for SE due to hypoxic brain damage, traumatic subarachnoid hemorrhage or subdural hemorrhage and sepsis had the worst clinical outcome. The 30-day mortality rates were 33.3% for hypoxic brain damage, 50% for cases with sepsis and 50% in subjects admitted for traumatic subarachnoid hemorrhage or subdural hemorrhage.
Comparisons between patients with previous history of epilepsy and patients with no previous history of epilepsy
Twenty-nine patients (33.3%) had previous history of epilepsy while 58 patients (66.7%) had no previous history of epilepsy before the status epilepticus episode (Table 3) . Patients without previous history of epilepsy were older than those with history of epilepsy (52 Vs 43, p = 0.009). Subjects presenting with de novo status epilepticus were more likely to have non-convulsive status epilepticus (NCSE) (15.5% vs. 0%, p = 0.026). De novo status epilepticus was associated with longer status duration (median 2.5 days, IQR 5 days), and longer ICU stay (median 7.5 days, IQR 9 days). They were also more likely to have poorer outcome upon discharge (OR 4.15, 95% CI 1.53-11.2) ( Table 3 ).
Discussions
In this study, patients with de novo status epilepticus were older. De novo status epilepticus was associated with higher risk of developing non-convulsive status epilepticus, having longer status duration, longer ICU stay and poorer clinical outcome. This might reflect the fact that de novo status epilepticus was associated with more serious brain insults, e.g. cerebral vascular accidents and central nervous system infection, which were shown to be independently associated with poor outcome [14] . Breakthrough seizure was the most common etiology in patients with preexisting history of epilepsy. A study reported that status epilepticus due to low anti-convulsants levels or recent change in medication was associated with good clinical outcome, of which 78% were non-refractory [15] .
In another study focusing on the treatment of refractory status epilepticus with propofol [16] , subjects with anti-convulsants withdrawal had better clinical outcomes. A systematic review concluded that the reduction or withdrawal of anti-convulsants was a common cause of SE in patients with a history of epilepsy and are associated with better prognosis even in patients with refractory SE [17] .
In this study, one-sixth patients with no previous history of epilepsy developed first episode of seizure as non-convulsive status epilepticus. This reflected the need for higher vigilance in diagnosis. NCSE would be missed without continuous EEG. In a study which included 57 consecutive patients who underwent continuous EEG (cEEG) monitoring over a 6.5-year period, seizures were detected in 19% of patients who underwent cEEG monitoring and the seizures were exclusively nonconvulsive in 92% of these patients [18] . Use of continuous EEG monitoring was strongly advocated.
Continuous EEG monitoring has been advocated in western countries as an essential bedside neurophysiological tool to detect epileptic activity and help predict prognosis. One study showed that 37% of patients with unexplained alteration of consciousness had EEGs suggesting of NCSE [19] . Another study that excluded patients with convulsive seizures found that 8% of ICU patients who were evaluated for coma with EEG had NCSE [20] .
Using continuous EEG monitoring, more than half of all seizures could be detected in the first hour, and up to 80% the first 24 h [18] . Loss of electroencephalographic variability and reactivity might indicate severe cerebral dysfunction and reflect poor prognosis [21] . Implementation of continuous EEG monitoring for at least 24 h in patients admitting to intensive care units due to SE and all patients in intensive care units with unexplained coma or mental states was suggested by J Classen [18] . Despite the benefit of continuous EEG monitoring, its implementation might be challenging. Misinterpretations of benign variants as epileptic discharge are not uncommon [22] . This might lead to erroneous diagnosis and unnecessary treatments [23] . To obtain the correct diagnosis, it requires high level of expertise in on-site interpretation of the EEG findings. Hence, further training on EEG interpretation among ICU physicians and making a library of artifacts would be essential [24] .
This study, being a retrospective study, had several limitations. Firstly, the results depended on the records of the case notes. The qualities of recording and accuracy on the description of the seizure on presentation vary, contributing to information bias.
Secondly, not all patients admitted to the intensive care unit received an EEG assessment in view of limited availability of service. The diagnosis of NCSE was limited to those in which EEG was performed, resulting in a probable under-identification of NCSE.
As in all retrospective analysis, possible confounders might exist. Patients with SE might have multiple comorbidities predisposing to SE. It was difficult to establish the causal relationship of the type of seizure and the clinical outcome. Despite the limitations, this study was able to identify clinical characteristics and prognostic factors in patients presenting with status epilepticus, especially in subjects with de novo SE.
In future, a prospective case control study would help minimize bias and confounders in evaluating the association among the forms of status epilepticus, the etiologies and the clinic outcome.
Conclusions
Non-convulsive status epilepticus was more common in patients with no previous history of epilepsy. De novo status epilepticus was associated with longer status duration, longer ICU stay and poorer outcome. Early diagnosis of non-convulsive status epilepticus especially in patients with de novo status epilepticus is important. Use of continuous EEG monitoring might help in detecting non-convulsive status epilepticus and might help improve clinical outcomes.
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